Prognostic value of response after three MOPP cycles in hodgkin's disease ? stage III and IV
- 1 March 1987
- journal article
- research article
- Published by Springer Nature in Annals of Hematology
- Vol. 54 (3) , 171-177
- https://doi.org/10.1007/bf00320373
Abstract
Sixty-eight patients with Hodgkin's disease stage III and IV were evaluated after three out of six MOPP cycles. At that time, 46 (68%) were classified as early responders and 22 as slow responders. The criteria of response were: disappearance of B symptoms, decrease in the size of the largest lymph nodes (by more than 50%) and significant reduction (more than 20%) of mediastinal enlargement. Out of 43 early responders, 38 were in complete remission after six MOPP cycles and only five out of 22 slow responders. Such an early response is only related to the absence of B symptoms at the time of diagnosis (p<0.05). The survival curves of early responders and slow responders were significantly different (p50 mm) was the most frequently abnormal sign found in the group not responding after three MOPP cycles (p<0.0001). Such a significant prognostic value of early response is observed for stage III but not for stage IV patients. We conclude that early clinical response after three MOPP cycles is a good prognostic factor which must be kept in mind in the formulation of the therapeutic regimen for Hodgkin's disease stage III and IV.This publication has 11 references indexed in Scilit:
- Early response to chemotherapy as a prognostic factor in Hodgkin's diseaseCancer, 1983
- Diagnosis and management of Hodgkin's disease in the adultCancer, 1983
- Treatment of MOPP-refractory Hodgkin-s disease with vinblastine, doxorubicin, bleomycin, CCNU, and dacarbazineCancer, 1983
- Comparison of adriamycin-containing chemotherapy (MOP-BAP) with MOPP-bleomycin in the management of advanced Hodgkin-s disease a southwest oncology group studyCancer, 1983
- Acute myeloid leukemia following treatment of hodgkin's disease. A reviewCancer, 1982
- A new effective four-drug combination of CCNU (1-[2-chloroethyl]-3-cyclohexyl-1-nitrosourea) (NSC-79038), vinblastine, prednisone, and procarbazine for the treatment of advanced Hodgkin's diseaseCancer, 1980
- Curability of Advanced Hodgkin's Disease with ChemotherapyAnnals of Internal Medicine, 1980
- A comparative study of a bcnu containing 4-drug program versus mopp versus 3-drug combinations in advanced Hodgkin's disease.A cooperative study by the cancer and leukemia group BCancer, 1979
- Systematic restaging in patients with Hodgkin's disease.A southwest oncology group studyCancer, 1978
- Combination Chemotherapy in the Treatment of Advanced Hodgkin's DiseaseAnnals of Internal Medicine, 1970